Gilead Sciences (GILD) Tops Q2 EPS by 14c

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.87, $0.14 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.2 billion versus the consensus estimate of $6.07 billion.

GUIDANCE:

Gilead Sciences sees FY2021 EPS of $6.90-$7.25, versus the consensus of $7.07. Gilead Sciences sees FY2021 revenue of $24.4-25 billion, versus the consensus of $24.64 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance